Ken Griffin Tyra Biosciences, Inc. Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
Call Options
2 transactions
Others Institutions Holding TYRA
# of Institutions
77Shares Held
32.4MCall Options Held
600Put Options Held
3.7K-
Boxer Capital, LLC San Diego, CA6.45MShares$103 Million5.5% of portfolio
-
Bvf Inc San Francisco, CA4.66MShares$74.5 Million2.29% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.41MShares$70.5 Million79.77% of portfolio
-
Nextech Invest Ag4.06MShares$64.9 Million12.44% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.99MShares$31.8 Million3.43% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $671M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...